leadXpro at the PSDI conference
Michael Hennig (CEO, leadXpro) will chair and open the session on „Membrane proteins & hot structures“ at the PSDI 2016 conference with a talk on „Extension of structure based drug discovery on membrane proteins, update on recent developments and examples“. Additional technical detail into this topic will be provided by Robert Cheng presenting a poster titled „leadXpro: Structure based drug design on membrane protein targets“.
The scientific meeting „PSDI 2016, the 24th Protein Structure Determination in Industry Conference“ will take place in Malmö, Sweden on 13-15 November. This conference series (http://www.psdi2016.org/) brings together scientists and research managers in the pharmaceutical industry to discuss advances in the area of structure based drug discovery.
Conference participants are encouraged to use this opportunity to discuss with leadXpro presenters in person.
About leadXpro AG
leadXpro is a lead discovery company focusing on membrane protein drug targets. We are committed to the application of biophysical and structure-based methods for the discovery and optimization of next generation lead compounds. leadXpro’s technology platform enables structural determination of membrane proteins where classical crystallographic techniques fail, unlocking structure-based drug discovery for challenging targets. We capitalize on the knowledge regarding membrane protein structural biology and facilities of the Paul Scherrer Institute (PSI) with premium access to the synchrotron Swiss Light Source (SLS) and the Free Electron Laser (SwissFEL). Core expertise beyond X-ray include single particle cryo-electron microscopy (cryo-EM) and electron diffraction (ED). For more information, please visit www.leadxpro.com
leadXpro is a registered trademark in the EU, Switzerland, US and Canada.
Michael Hennig, CEO